Peptide Guide + Calculator
Ipamorelin Reconstitution Calculator & Guide
Growth Hormone Secretagogue / Ghrelin Receptor Agonist
Ipamorelin is an investigational growth hormone secretagogue and ghrelin-receptor agonist that has been studied for its ability to stimulate growth hormone release. Human research exists, but it is limited and does not establish the broad recovery, sleep, muscle-building, or fat-loss claims commonly discussed online. This page explains the available human evidence, safety and regulatory status, comparisons with CJC-1295, and educational reconstitution math.
Evidence Snapshot
Ipamorelin research at a glance
Standardized regulatory and evidence context so research compounds, investigational drugs, and approved medications are not treated as if they have the same level of human evidence.
Regulatory status
Not FDA-approvedDevelopment / evidence stage
Phase 2 (historical)
Historical clinical development
Human evidence level
Human pharmacology / early clinicalPrimary mechanism
Ghrelin-receptor / growth-hormone-secretagogue receptor agonist that stimulates GH release.
WADA context
Explicitly prohibited — S2Human intervention evidence
Early pharmacology studies and a Phase 2 postoperative-ileus development program exist, but they do not establish the recovery, muscle-building, fat-loss, or sleep claims commonly discussed online.
Human biology evidence
Human pharmacology studies demonstrate growth-hormone release after ipamorelin exposure.
Key takeaway
There is direct human evidence that ipamorelin can stimulate GH release, but that is not the same as evidence for recreational performance or recovery benefits.
Evidence labels describe the research base and regulatory context; they are not treatment, dosing, or use recommendations. Review dates describe the last BACToBasics source check for this evidence summary. Anti-doping rules can change and should be verified with the applicable authority.
Ipamorelin Reconstitution Calculator
Enter the vial amount, liquid volume, and amount you want to calculate. BACToBasics will automatically calculate concentration, liquid volume, and U-100 syringe-unit equivalents.
Loading calculator...
Calculator values are educational math inputs only. They are not recommended preparation amounts, doses, or use protocols.
Ipamorelin Reconstitution Math
Reconstitution math starts with the amount contained in the vial and the liquid volume used in the calculation. Dividing the vial amount by the liquid volume gives the resulting concentration.
Example vial amount
5 mg
| Liquid Volume | Calculation | Concentration |
|---|---|---|
| 1 mL | 5 mg ÷ 1 mL | 5 mg/mL |
| 2 mL | 5 mg ÷ 2 mL | 2.5 mg/mL |
| 3 mL | 5 mg ÷ 3 mL | 1.6667 mg/mL |
This table demonstrates concentration math only. The liquid volumes shown are examples for comparison and are not preparation recommendations.
More Reconstitution Tools
Need to compare different liquid volumes or convert between mg, mcg, mL, and U-100 units? Use the dedicated BACToBasics calculator tools.
What is Ipamorelin?
Ipamorelin is a synthetic peptide classified as a growth hormone secretagogue. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor, and can stimulate release of growth hormone from the pituitary. Ipamorelin is not an FDA-approved medication.
How does Ipamorelin work?
Ipamorelin activates the growth hormone secretagogue receptor, a receptor also activated by the hormone ghrelin. In human pharmacology research, intravenous Ipamorelin produced a distinct episode of growth hormone release. This mechanism differs from growth hormone-releasing hormone analogs such as CJC-1295, which stimulate the growth hormone axis through the GHRH receptor.
What has human research shown?
A pharmacokinetic and pharmacodynamic study in healthy male volunteers showed that Ipamorelin exposure increased proportionally across the studied infusion levels and produced a single episode of growth hormone release. The reported terminal half-life was approximately two hours. These findings demonstrate biological activity in humans but do not establish clinical benefits for muscle growth, fat loss, recovery, anti-aging, or sleep.
How much clinical evidence exists for Ipamorelin?
Human clinical evidence is limited. In addition to early pharmacology studies, a randomized Phase 2 trial evaluated intravenous Ipamorelin in 117 patients after bowel resection for postoperative ileus. The trial did not find a statistically significant improvement in its key efficacy endpoint compared with placebo. The available human studies do not establish an approved therapeutic use for Ipamorelin.
Ipamorelin for muscle growth and recovery
Ipamorelin is frequently marketed or discussed online for muscle growth, workout recovery, and improved body composition because it can stimulate growth hormone release. However, the human studies demonstrating growth hormone release are not the same as clinical trials showing improved muscle mass, strength, injury recovery, or athletic performance. Those broader claims remain unproven.
Ipamorelin for fat loss
Fat-loss claims are also commonly associated with Ipamorelin in online peptide communities. Human pharmacology studies show that Ipamorelin can affect growth hormone signaling, but there is not strong clinical evidence demonstrating that Ipamorelin itself produces meaningful or predictable fat loss in humans.
Ipamorelin and sleep
Ipamorelin is often discussed online in connection with sleep quality because natural growth hormone secretion is linked with sleep physiology. However, evidence that Ipamorelin improves sleep outcomes in humans is limited, and sleep improvement should not be treated as an established clinical effect.
Ipamorelin vs CJC-1295
Ipamorelin and CJC-1295 act through different receptors within the growth hormone axis. Ipamorelin is a ghrelin-receptor or growth hormone secretagogue receptor agonist, while CJC-1295 is a growth hormone-releasing hormone analog that acts through the GHRH receptor. This mechanistic difference is why the two are often discussed together online, but popularity of the combination does not establish that the combination is safe, effective, or clinically validated.
Ipamorelin vs growth hormone
Ipamorelin is not growth hormone. It is a secretagogue intended to stimulate the body's own growth hormone release through receptor signaling. Recombinant human growth hormone directly supplies growth hormone and has FDA-approved medical indications. The safety, effectiveness, regulatory status, and clinical evidence for these substances are therefore very different.
What is known about Ipamorelin safety?
The safety profile of Ipamorelin is not well established for the injectable uses commonly discussed online. FDA has cited potential immunogenicity concerns related to aggregation, peptide-related impurities, and the presence of unnatural amino acids. FDA has also stated that it lacks sufficient safety information for certain injectable routes and that risks associated with increased IGF-1 signaling, including glucose intolerance and fluid retention, remain relevant considerations.
What happened in the postoperative ileus trial?
In the Phase 2 postoperative ileus study, overall treatment-emergent adverse events were common in both the Ipamorelin and placebo groups because participants had undergone bowel surgery. FDA's later review noted higher rates of hypokalemia and hyperglycemia in the Ipamorelin group and discussed two deaths among Ipamorelin-treated participants. The original study did not establish that the deaths were caused by Ipamorelin, but FDA cited the findings as part of its safety concerns when evaluating compounded Ipamorelin.
Is Ipamorelin FDA-approved?
No. There is no FDA-approved Ipamorelin drug product. FDA has evaluated Ipamorelin-related bulk drug substances in the compounding context and identified significant unresolved safety and evidence concerns. In 2024, the Pharmacy Compounding Advisory Committee voted against placing Ipamorelin free base and Ipamorelin acetate on the 503A Bulks List.
Is Ipamorelin banned in competitive sports?
Yes. The World Anti-Doping Agency's 2026 Prohibited List includes Ipamorelin among growth hormone secretagogues and their mimetics. It is prohibited at all times for athletes subject to WADA rules.
Research Ipamorelin vs an approved medication
Products sold online as research or compounded Ipamorelin should not be treated as equivalent to an FDA-approved pharmaceutical product. No FDA-approved Ipamorelin product exists with an approved indication, standardized labeling, established clinical dosing regimen, or an FDA-reviewed safety and effectiveness profile.
Ipamorelin reconstitution math
Reconstitution calculations depend on the labeled amount in a vial and the liquid volume used. As a mathematical example, a 5mg vial combined with 2mL of liquid produces a concentration of 2.5mg per mL, or 2,500mcg per mL. BACToBasics uses examples like this only to demonstrate concentration, liquid-volume, and U-100 syringe-unit calculations rather than to recommend an Ipamorelin preparation or dosing protocol.
Explore more about Ipamorelin
16 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Explore more about Ipamorelin
16 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Compare Ipamorelin
Direct comparison pages are selected from the indexable BACToBasics comparison catalog and update automatically as that catalog grows.
CJC-1295 vs Ipamorelin
Compare CJC-1295, Ipamorelin using the same evidence dataset.
Open →
ComparisonTesamorelin vs Ipamorelin
Compare Tesamorelin, Ipamorelin using the same evidence dataset.
Open →
ComparisonTesamorelin vs CJC-1295 vs Ipamorelin
Compare Tesamorelin, CJC-1295, Ipamorelin using the same evidence dataset.
Open →
Research, updates & development
Jump from the guide into the public update timeline, compound-specific research records, and clinical-development tracker without searching again.
Ipamorelin research & development updates
Open the public timeline of sourced research records and material development changes tracked by BACToBasics.
Open →
ResearchIpamorelin research sources
Open 2 curated research records for Ipamorelin.
Open →
DevelopmentIpamorelin clinical development
Phase 2 (historical) · Historical clinical development. Completed Phase 2 postoperative-ileus study, NCT00672074.
Open →
Blend guides containing Ipamorelin
These pages are derived from blend component metadata, so a new blend automatically becomes discoverable from each linked component guide.
CJC-1295 + Ipamorelin
Fixed-ratio vial-label math for a CJC-1295 + Ipamorelin blend.
Open →
Blend guideTesamorelin + Ipamorelin
Label-based math for marketed Tesamorelin + Ipamorelin blend vials with variable ratios.
Open →
Blend guideSermorelin + Ipamorelin
Fixed-ratio vial math for marketed Sermorelin + Ipamorelin combinations.
Open →
Related peptide guides
Related guides are ranked from shared comparison pages, shared blend pages, and peptide category rather than a hand-maintained link list.
CJC-1295 guide & calculator
Growth Hormone & Performance · Long-Acting Growth Hormone-Releasing Hormone Analog
Open →
Peptide guideTesamorelin guide & calculator
Growth Hormone & Performance · Growth Hormone-Releasing Hormone Analog
Open →
Peptide guideSermorelin guide & calculator
Growth Hormone & Performance · GHRH(1-29) Analog
Open →
Peptide guideGHRP-2 guide & calculator
Growth Hormone & Performance · Pralmorelin / GH-Releasing Peptide-2
Open →
Relevant glossary concepts
Definitions are matched against the guide's structured title, subtitle, description, and educational sections.
FDA-Approved
A status indicating that the FDA has approved a specific drug product for one or more labeled uses after reviewing the required evidence and manufacturing information.
Open →
GlossaryMilliliter (mL)
A metric unit of liquid volume equal to one-thousandth of a liter.
Open →
GlossaryAgonist
A molecule that binds to a receptor and activates signaling through that receptor.
Open →
Ipamorelin FAQ
Tap a question to expand only the answer you want to read.
Is Ipamorelin FDA-approved?
No. Ipamorelin is not an FDA-approved medication. FDA has evaluated Ipamorelin-related bulk drug substances in the compounding context and has identified unresolved safety and evidence concerns.
Does Ipamorelin increase growth hormone?
Yes, human pharmacology research has shown that Ipamorelin can stimulate growth hormone release. Demonstrating a growth hormone response does not by itself establish clinical benefits such as greater muscle mass, fat loss, improved recovery, or better sleep.
What receptor does Ipamorelin target?
Ipamorelin acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor. Activation of this receptor can stimulate pituitary growth hormone release.
What is the half-life of Ipamorelin?
A human intravenous pharmacokinetic study reported a terminal half-life of approximately two hours. Pharmacokinetics can depend on formulation and route of administration, so that finding should not be generalized to every product or route.
Does Ipamorelin build muscle?
There is not strong controlled human evidence establishing Ipamorelin as a muscle-building treatment. Its ability to stimulate growth hormone release should not be treated as proof of increased muscle mass or strength.
Does Ipamorelin burn fat?
There is not strong clinical evidence showing that Ipamorelin itself produces meaningful, predictable fat loss in humans. Online fat-loss claims go beyond what the current human evidence establishes.
Does Ipamorelin improve sleep?
Sleep improvement is commonly discussed online, but there is insufficient clinical evidence to treat improved sleep as an established effect of Ipamorelin.
Why are Ipamorelin and CJC-1295 compared or combined?
They act through different receptors in the growth hormone axis: Ipamorelin through the ghrelin or growth hormone secretagogue receptor and CJC-1295 through the GHRH receptor. That mechanistic distinction explains the online interest in combining them, but it does not establish that the combination is safe or effective.
Is Ipamorelin the same as HGH?
No. Ipamorelin is a growth hormone secretagogue that stimulates signaling intended to trigger endogenous growth hormone release. HGH refers to growth hormone itself.
What are the side effects of Ipamorelin?
A reliable side-effect profile for the injectable uses commonly discussed online has not been established. FDA has raised concerns involving immunogenicity, peptide impurities, glucose-related effects, and limited safety data for certain routes of administration.
Is Ipamorelin banned by WADA?
Yes. Ipamorelin is listed by WADA among prohibited growth hormone secretagogues and is prohibited at all times for athletes subject to WADA rules.
How do you calculate Ipamorelin reconstitution concentration?
Divide the labeled vial amount by the liquid volume. For example, 5mg divided by 2mL equals 2.5mg/mL, or 2,500mcg/mL. This is concentration math rather than a recommendation for how an Ipamorelin product should be prepared.
Can the BACToBasics calculator handle Ipamorelin math?
Yes. Enter a labeled vial amount and liquid volume to calculate concentration, equivalent liquid volume, U-100 syringe units, and approximate amounts per vial. BACToBasics provides educational math rather than medical or dosing advice.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Sources & References
6 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
FDA identifies potential immunogenicity, aggregation, impurity, and active-ingredient-characterization concerns and states that safety information is insufficient for certain injectable routes.
FDA review of Ipamorelin-related bulk drug substances, including available human evidence, safety concerns, lack of subcutaneous clinical safety data, and the proposal not to add Ipamorelin to the 503A Bulks List.
Meeting summary documenting the advisory committee's vote against placing Ipamorelin free base and Ipamorelin acetate on the 503A Bulks List.
Human pharmacology study in healthy male volunteers characterizing Ipamorelin exposure and growth hormone response. PMID: 10496658. DOI: 10.1023/A:1018955126402.
Multicenter randomized placebo-controlled trial in bowel-resection patients. The key efficacy endpoint did not differ significantly between Ipamorelin and placebo. PMID: 25331030.
Ipamorelin is listed among growth hormone secretagogues and their mimetics and is prohibited at all times for athletes subject to WADA rules.
BACToBasics provides educational information and math tools only. This content is not medical advice, dosing advice, injection instruction, or a recommendation to use any peptide or medication.